AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.41 and traded as high as $10.78. AngioDynamics shares last traded at $10.33, with a volume of 356,560 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright lifted their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, January 10th.
View Our Latest Stock Report on ANGO
AngioDynamics Trading Down 2.2 %
The stock has a 50-day moving average price of $10.73 and a 200 day moving average price of $8.46. The stock has a market capitalization of $399.03 million, a price-to-earnings ratio of -1.75 and a beta of 0.60.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. AngioDynamics's quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the company earned ($0.05) earnings per share. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.
Insiders Place Their Bets
In other news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.40% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ANGO. Systematic Financial Management LP increased its stake in AngioDynamics by 4.6% during the 4th quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier's stock worth $23,093,000 after buying an additional 110,719 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of AngioDynamics by 10.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier's stock worth $13,636,000 after purchasing an additional 135,007 shares in the last quarter. Segall Bryant & Hamill LLC raised its stake in AngioDynamics by 55.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock valued at $12,963,000 after purchasing an additional 503,713 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in AngioDynamics by 37.4% in the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier's stock valued at $11,875,000 after purchasing an additional 353,070 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock worth $10,254,000 after purchasing an additional 133,312 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.
About AngioDynamics
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Further Reading
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
